Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Recent studies by C. Bunnell and co-authors add new data to breast cancer findings
August 7th, 2008
According to a study from the United States, "The aim of this study was to determine the safety, maximum tolerated dose (MTD), recommended phase II dose, and efficacy of the epothilone B analogue ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer (MBC). A total of 106 patients were enrolled." "The study consisted of a dose-escalation phase (phase I) and a tumor response rate evaluation phase (phase II). Seventy-four patients were treated in phase I with schedule A (ixabepilone 40 mg/m(2) intravenously on day 1 plus capecitabine 1650-2000 mg/m(2) on days 1-14 of a 21-day cycle) or schedule B (ixabepilone 8-10...
Source: Women's Health Weekly (2008-08-07)
|
